Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetes

Jaime L Peters,1 Rob Anderson,2 Chris Hyde2

ABSTRACT

Objectives: To describe the development process for defining an appropriate model structure for the economic evaluation of test–treatment strategies for patients with monogenic diabetes (caused by mutations in the GCK, HNF1A or HNF4A genes).

Design: Experts were consulted to identify and define realistic test–treatment strategies and care pathways. A systematic assessment of published diabetes models was undertaken to inform the model structure.

Setting: National Health Service in England and Wales.

Participants: Experts in monogenic diabetes whose collective expertise spans the length of the patient care pathway.

Primary and secondary outcomes: A defined model structure, including the test–treatment strategies, and the selection of a published diabetes model appropriate for the economic evaluation of strategies to identify patients with monogenic diabetes.

Results: Five monogenic diabetes test–treatment strategies were defined: no testing of any kind, referral for genetic testing based on clinical features as noted by clinicians, referral for genetic testing based on the results of a clinical prediction model, referral for genetic testing based on the results of biochemical and immunological tests, and referral for genetic testing for all patients with a diagnosis of diabetes under the age of 30 years.

The systematic assessment of diabetes models identified the IMS CORE Diabetes Model (IMS CDM) as a good candidate for modelling the long-term outcomes and costs of the test–treatment strategies for monogenic diabetes. The short-term test–treatment events will be modelled using a decision tree which will feed into the IMS CDM.

Conclusions: Defining a model structure for any economic evaluation requires decisions to be made. Expert consultation and the explicit use of critical appraisal can inform these decisions. Although arbitrary choices have still been made, decision modelling allows investigation into such choices and the impact of assumptions that have to be made due to a lack of data.

INTRODUCTION

Monogenic diabetes, caused by mutations in the GCK, HNF1A or HNF4A genes, differs to known type 1 and type 2 diabetes in terms of disease progression and the treatments patient receive. Rather than the more invasive and expensive treatment of subcutaneous insulin, patients with HNF1A and HNF4A mutations can be successfully treated with sulfonylureas, while patients with GCK mutation rarely require pharmacological treatment.1–5 The challenge is to diagnose monogenic diabetes, as many patients with monogenic diabetes will be mislabelled as having type 1 or type 2 diabetes and will continue to inject insulin.

Diabetes has a substantial clinical impact on the patient’s health and well-being, in addition to being a large economic burden for healthcare systems. It is estimated that most people with monogenic diabetes are initially inappropriately managed due to misdiagnosis.6,7 Identifying patients with monogenic diabetes and selecting the appropriate treatment option should lead to reduced treatment costs and improved health status.
Development of an economic evaluation of diagnostic strategies

for patients. Genetic testing for monogenic diabetes is available via the National Health Service in England and Wales (NHS) and costs £350 per test. However, evidence indicates varied patterns of referral rates for genetic testing for monogenic diabetes across geographical regions in the NHS. Approaches to improve the identification of patients eligible for genetic testing of monogenic diabetes exist: improving the awareness and understanding of monogenic diabetes in healthcare professionals, the development of statistical clinical prediction models, and the use of two phenotype-based tests to (1) measure biochemical levels using the urinary C-peptide creatinine ratio (UCPCR) and (2) identifying the presence of pancreatic autoantibodies. Using such approaches alongside genetic testing and followed by appropriate treatment selection (oral sulfonylurea or a controlled diet) has the potential to inform the effective, safe and cost-effective management of people with monogenic diabetes. To date, there has been no robust evaluation to assess the most cost-effective approaches to identify patients with monogenic diabetes.

Modelling test–treatment strategies has many challenges. These include a greater number of strategies to be considered due to different sequences or combinations of tests, and the greater complexity of such models to reflect not only the initial testing aspects, but also any follow-up testing, treatment and monitoring of patients. Thus, it is important to accurately reflect the test–treatment strategies and associated care pathways when building a model. Each structural choice involves a consideration of the inclusion of specific parameters, the definition of those parameters, how they relate to other parameters in the model and the availability of research or other evidence to inform them. As the model structure impacts on all parts of the study, even on the results of the cost-effectiveness modelling, it is essential that the structure is informed, defensible and explicit. The aim of this study is to describe the development process for defining an appropriate model structure for test–treatment strategies for monogenic diabetes. There were two specific objectives: (1) to identify the number of possible test and treatment strategies that are potentially feasible to target the treatment of people with monogenic diabetes and (2) to select an appropriate model type and structure to represent the identified test–treatment strategies and subsequent impact on care pathways.

This economic evaluation forms a part of a larger project: Using genetics to Improve Treatment of Early-onset Diabetes—the UNITED study (see http://www.hicfund.org.uk/HICFundPortfolio/Theme1.aspx). The main aims of the UNITED study are (1) to estimate the prevalence of monogenic diabetes in the UK and (2) to provide evidence for a systematic care pathway for the diagnosis and treatment of patients with monogenic diabetes.

In the Methods section, the methods used to identify and define realistic test–treatment strategies and the selection of a long-term diabetes model are described. In the Results section, the defined test–treatment strategies and model structure (including assumptions and likely data sources) are given in detail. Challenges and limitations in the development of an economic evaluation of test–treatment strategies in monogenic diabetes are discussed, followed by brief conclusions.

METHODS
Defining test–treatment strategies and care pathways
The identification and definition of care pathways was undertaken iteratively through discussion with a number of experts. A meeting was held with the consultant physician, the diabetes nurse and the project coordinator for the UNITED study. During this initial meeting, discussion was centred on the test–treatment strategies that were feasible for patients with monogenic diabetes, and the care pathways associated with these strategies. Once possible test–treatment strategies were agreed upon, further development on the specificity of the strategies and the care pathways was undertaken through email, telephone and one-to-one meetings with individual members of the UNITED clinical team (in particular, the diabetes nurse, project coordinator and the clinical scientists) where necessary. When these were further defined, they were presented at a meeting with members of the UNITED clinical team (including diabetes nurses, clinical molecular geneticists and clinical scientists) and the UNITED study Steering Group for discussion. The UNITED study Steering Group consists of 12 members, including representatives from the UNITED study funding bodies, experts in diabetes, statistics and economic evaluation. The collective expertise of the Steering Group and the UNITED study clinical team spans the length of the care pathway. Further detailing and amendments to the proposed test–treatment strategies were made as a result of these discussions.

Defining model structure
A systematic assessment of diabetes models available in the published literature was undertaken to help inform the type and structure of the decision model to be used. The diabetes models that were assessed were those evaluated in two recent reviews of diabetes models by Yi et al and Tarride et al. Criteria for diabetes models from the American Diabetes Association (ADA) and criteria specific to the needs of this economic evaluation were used to assess the established models. These criteria included demonstrated internal and external validity, a long-term time horizon, interdependence between modelled complications, capture of glycated haemoglobin, analysis of quality-adjusted life-years (QALYs) and previous use in the published literature and in health technology assessment (HTA) submissions to reimbursement organisations. Taking information from the descriptive articles for these models and information
reported in Yi et al and Tarride et al, the assessment criteria were applied to each diabetes model.

RESULTS
Test–treatment strategies and care pathways
Based on discussions with experts, five strategies were defined to represent realistic options within the NHS, and are summarised in Table 1.

Strategy 1 is the most basic strategy where no patients are referred for genetic testing, and therefore no treatment change is modelled for any patient. This strategy represents the current situation as seen by the National Institute for Health and Clinical Excellence (NICE), since there is no NICE guidance specifically for monogenic diabetes as distinct from type 1 or type 2 diabetes.

Strategy 2 is intended to represent the observed current practice in the UK where some patients are referred for genetic testing based on their clinical features as noted by clinicians. Currently, referral for genetic testing is dependent on the knowledge and awareness of clinicians or diabetes nurses. Data from Shields et al demonstrate great variation in referral and diagnosis rates between different regions of the UK with the South West of England having the highest referral rate (105.9 per million regional population leading to a total of 28.4 cases per million) and Wales having the lowest referral rate (13.1 per million of the regional population leading to 12.4 cases per million).

Strategy 3 is modelled as a potential improvement on current practice (strategy 2), where referral for genetic testing is more systematic; yet it is still based on the clinical features of the patient. A clinical prediction model has been developed for identifying patients likely to have monogenic diabetes and is available online (http://www.diabetesgenes.org/content/monod-pm-calc).

Strategy 4 represents a systematic pathway consisting of biochemical (UCPCR) and immunological (pancreatic autoantibody) testing. While patients with monogenic diabetes continue to produce their own insulin, type 1 diabetes is characterised by insulin deficiency. C-peptide testing in blood has been identified as a marker of those patients producing their own insulin, and recent work has demonstrated that UCPCR is a good discriminator between type 1 patients and those with HNF1A, HNF4A or GCK mutations. However, patients newly diagnosed with type 1 diabetes are considered to be in a ‘honeymoon’ phase, where they continue to produce insulin of their own, up to 5 years post-diagnosis, and therefore will be UCPCR test positive.

For strategy 4 to be effective, a test to help distinguish between honeymoon type 1 patients and those with HNF1A, HNF4A or GCK mutations is needed. McDonald et al have identified pancreatic autoantibody testing for this purpose. The presence of these antibodies characterises type 1 diabetes, but their prevalence in cohorts of patients with monogenic diabetes is similar to the general population. Tests for two particular antibodies have been proposed and evaluated by McDonald et al: glutamate decarboxylase (GAD) and islet antigen-2 (IA-2). Strategy 4 is therefore defined by patients currently on insulin treatment being offered the UCPCR test. Those testing positive or not currently on insulin treatment (therefore producing their own insulin) will be offered the GAD and IA-2 tests. Patients testing negative for GAD and IA-2 will be referred for genetic testing on basis of prediction model.

| Table 1 | Test–treatment strategies for patients’ diagnosed with diabetes when <30 years |
|---------|--------------------------------------------------------------------------------------------------|
| Strategy | Definition                                                                                     | Treatment implications                          | Policy implications                                      |
| 1. No testing | No clinical, biochemical, immunological or genetic testing                                      | No treatment change offered. Patients with monogenic diabetes continue on treatment as from initial diagnosis | The situation as currently seen by NICE |
| 2. Current practice | Patients referred for genetic testing on basis of clinical features as noted by clinicians | Treatment change offered                        | Current practice likely to evolve over time with increasing awareness of monogenic diabetes. Costs associated with this strategy are also likely to change over time |
| 3. Prediction model | Patients referred for genetic testing on basis of prediction model                              | Treatment change offered                        | Information included in the prediction model is routinely collected. It is clear as to the basis on which referrals are made |
| 4. UNITED pathway | Biochemical, immunological and genetic testing. Patients undergo a series of tests: c-peptide (for those on insulin), autoantibodies, genetic | Treatment change offered                        | Clear definition on which to make referrals |
| 5. All tested | All patients diagnosed <30 years are referred for genetic testing                               | Treatment change offered                        | Will lead to increase in referrals at the UK referral centre |

NICE, National Institute for Health and Clinical Excellence; UNITED, Using genetics to Improve Treatment of Early-onset Diabetes.

Peters JL, Anderson R, Hyde C. BMJ Open 2013;3:e002905. doi:10.1136/bmjopen-2013-002905
negative for these antibodies will then be offered genetic testing for the HNF1A, HNF4A and/or GCK mutations.

Strategy 5 is modelled as the extreme to no testing (strategy 1) where all patients diagnosed with diabetes under 30 years of age are referred for genetic testing.

An important distinction between patients diagnosed with diabetes is the treatment they are currently receiving: patients not currently receiving insulin have demonstrated their ability to produce insulin and therefore do not have type 1 diabetes. In the economic evaluation, the possibility of different strategies being the most cost-effective screening strategy, depending on current treatment, will be assessed (see table 2 for the 25 different strategies defined by current treatment) in addition to the five strategies not distinguishing individuals by treatment (the 5 shaded strategies in table 2).

**Defining model structure**

To allow modelling of the short-term test–treatment events as well as their long-term consequences, a hybrid decision model will be used consisting of a decision tree (in MicroSoft Excel 2007) to model the short-term costs and benefits which will inform parameters in an established, long-term diabetes model.

**Decision tree**

Simplified versions of decision trees for test–treatment strategies 2–5 are shown in figures 1 and 2. Strategy 1 is not shown due to its simplicity: no testing or treatment change for anyone.

**Genetic testing**

Genetic testing is undertaken in strategies (2–5). A modelling assumption is that if a mutation is suspected in the HNF1A or HNF4A genes, both will be tested simultaneously. This is based on the current system at the UK referral centre for monogenic diabetes, the Royal Devon and Exeter NHS Foundation Trust (RDEFT), which allows simultaneous testing of HNF1A and HNF4A genes at a reduced cost. Assessment of clinical criteria for deciding whether the HNF1A and HNF4A gene mutations or the GCK gene mutation is initially tested is based on the judgement of experts in monogenic diabetes. These clinical criteria include patient age at diagnosis, BMI, any evidence of sensitivity to sulfonylureas, family history, HbA1c and fasting blood glucose among others. It is assumed that all positive genetic tests are correct, that is, that there are no false-positive genetic test results, and any negative tests are correct, that is, there are no false-negative test results.

Data on the decision as to whether a sample is initially tested for the HNF1A and HNF4A gene mutations or the GCK mutation are available from the current database of referrals to the UK referral centre.

**UCPCR test**

The UCPCR test is part of the UNITED strategy (strategy 4). This test is only offered to those in the modelled cohort currently receiving insulin treatment.
Patients testing positive for the UCPCR test are assumed to be producing their own insulin.

Thresholds for the UCPCR test that discriminates patients who are producing their own insulin from patients who are not have been identified for adults and children (unpublished data). In adults with a diagnosis of diabetes of \( \geq 5 \) years, a threshold of 0.2 nmol/mmol has 97% sensitivity and 96% specificity for discriminating patients with mutations in HNF1A or HNF4A genes from those with type 1 diabetes.

The optimum UCPCR thresholds for clinical practice may not necessarily be the optimum thresholds for cost-effectiveness. Therefore, in sensitivity analyses, the impact of assuming different UCPCR thresholds for discriminating monogenic diabetes from type 1 diabetes will be assessed on the estimates of cost-effectiveness.

Pancreatic autoantibody tests

Pancreatic autoantibody tests are also part of the UNITED strategy (strategy 4) to distinguish patients with monogenic diabetes from those with type 1 diabetes in the honeymoon phase. All patients testing positive for UCPCR and those patients who currently receive non-insulin treatment are offered the tests. As in practice, the two antibodies (GAD and IA-2) are tested simultaneously. If patients test negative for either of these antibodies, they are offered the genetic test.

Recent data are available on the ability of pancreatic autoantibody tests to discriminate between patients with mutations in GCK, HNF1A or HNF4A genes and those with type 1 diabetes. A negative GAD test had a sensitivity of 99% and a specificity of 62%, while a negative IA-2 test has a sensitivity of 100% and a specificity of 57%. However, by combining these tests so that a negative result from the GAD or the IA-2 test is defined as a negative result, greater discriminatory power is achieved: 99% sensitivity and 82% specificity.

Uptake and repeat tests

The uptake of testing may not be 100% in the screening strategies due to the fact that urine and blood samples are required and the decision tree will allow for this.

The model also allows for the possibility that some patients will be asked to provide more than one (urine or blood) sample for the C-peptide and autoantibody tests. Repeat tests (UCPCR, pancreatic autoantibody or genetic) on the same sample may also be required for some patients and these will be incorporated into the model.

For strategies 2, 3 and 5, it will be difficult to estimate the proportion of patients refusing referrals for genetic testing as these data do not exist. However, for strategy 4, data from the UNITED study will inform the uptake of genetic testing, as well as the uptake of the C-peptide and autoantibody tests. Estimates of uptake from the UNITED study will be used to inform the uptake of genetic testing in strategies 2, 3 and 5. Similarly, data on the proportion of additional urine and blood samples required from patients for repeat tests in strategy 4, and the number of repeat tests carried out, available from the UNITED study, will be used to inform estimates for strategies 2, 3 and 5.

Treatment

For all strategies involving a treatment change, only patients having a genetically confirmed diagnosis of monogenic diabetes due to mutations in the GCK, HNF1A and HNF4A genes will be offered a change in
treatment. Patients with the GCK mutation currently receiving treatment will be offered dietary advice so that they can stop treatment, whereas patients with the HNF1A or HNF4A mutation will be offered treatment transfer to sulfonylureas. Some patients may not cease insulin treatment, but with the addition of sulfonylureas, their insulin dose may be reduced.\(^5\) Data from the UNITED study will be used to inform this aspect of the model. The impact of any non-compliance of the current or new treatment will be modelled, as will any treatment-related adverse events, for example, mild hypoglycaemia when transferring from insulin to sulfonylureas.\(^5\) There may also be an increase in home blood glucose monitoring during treatment transfer. The model will allow for the possibility that some patients may refuse or fail treatment transfer. If patients do not have a test for monogenic diabetes or have a negative genetic test result, it is assumed that they will continue on their current treatment.

**Time horizon**

The decision tree time horizon will be long enough to capture all costs and health-related outcomes up until 12 months after patients with monogenic diabetes have attempted treatment transfer onto sulfonylureas or diet, as appropriate. The UNITED strategy has the longest time delay before patients attempt treatment change, and so, based on this strategy, the time horizon for the decision tree will be 16 months in the base case analyses.

**Long-term diabetes model**

A total of 11 diabetes models, described in Yi et al\(^{21}\) and/or Tarride et al,\(^{21}\) were reviewed. They were the IMS CDM,\(^{28}\) UKPDS,\(^{29}\) Archimedes,\(^{30}\) EAGLE,\(^{31}\) DCCT,\(^{32}\) DMM,\(^{33}\) Eastman,\(^{34}\) GDM,\(^{36}\) JADE,\(^{37}\) DiDAC,\(^{38}\) and CDC models. The results from applying the assessment criteria defined in the ‘Defining model structure’ section to these 11 models are given in web appendix 1. For some of the diabetes models, not enough evidence could be found to evaluate all the criteria. However, a number of diabetes models met all or many of the criteria including the IMS CDM,\(^{28}\) the UKPDS model,\(^{29}\) the Archimedes model\(^{30}\) and the Eagle model.\(^{31}\) We identified the IMS CDM in particular as it corresponds to the ADA modelling criteria, was well received at the fourth Mount Hood challenge,\(^{40}\) has been used in NICE HTAs\(^{41}\) as well as in HTAs worldwide.\(^{42} 43\) and has been developed over a period of 12 years.

Details on the IMS CDM have been described and summarised in a number of published articles (eg, Palmer et al,\(^{28}\) Yi et al\(^{21}\) and Tarride et al\(^{21}\)). It uses 15 Markov sub-models to simulate outcomes and costs for type 1 and type 2 diabetes patient cohorts, covering a range of macrovascular, microvascular and treatment-related complications with interaction between the sub-models.\(^{28}\) Baseline patient characteristics contribute to the calculation of the clinical outcomes and their costs, as do the risk factors such as age, duration of diabetes, HbA1c, body mass index (BMI) and treatment.

Data on HbA1c, age, weight, sex, duration of diabetes and current treatment, informed by the UNITED study, as well as the total costs and health outcomes from the short-term decision tree model will feed into the long-term diabetes model, so that total costs and outcomes can be calculated for each strategy.

**Study population**

The economic evaluation will consider all patients under the age of 30 years who are diagnosed with diabetes, regardless of whether they are insulin-treated or not. The cut-off of 30 years is based on evidence indicating that patients with monogenic diabetes are generally diagnosed with diabetes by this age, but usually misdiagnosed with type 1 diabetes.\(^{44} 45\) The cost-effectiveness of different test–treatment strategies will be evaluated in a prevalent cohort of patients, as well as in a mixture of prevalent and future incident cohorts to evaluate the cost-effectiveness of strategies should they be rolled out on a permanent basis.\(^{45}\)

**Disease progression**

Data relevant to the long-term outcomes of patients with the HNF1A mutation are available from two papers: Steele et al\(^{16}\) and Isomaa et al\(^{19}\). Steele et al\(^{16}\) report on the risk of mortality (cardiovascular and all cause) in HNF1A patients compared to non-diabetic family members in the UK from a retrospective analysis. Isomaa et al\(^{19}\) report the prevalence of diabetic complications in HNF1A, type 1 and type 2 patients in Finland in a cross-sectional study. Both these studies are limited by the study design (Isomaa et al is cross-sectional, Steele et al is retrospective). However, as the identification of monogenic diabetes is relatively new, there are less long-term data available, which will therefore be subject to greater uncertainty than for type 1 or type 2 diabetes.

**Health-state utility values**

For base case analyses, utility values will be defined using the EQ-5D where possible, in line with NICE’s preferred method.\(^{40}\) EQ-5D data are being collected in the UNITED study and will inform the short-term decision model. Utility values, those from the EQ-5D for a UK population, if available, will be sought from the literature for the long-term model.

**Resource use and costs**

Patterns of resource use by patients will differ by screening strategy. The hybrid model will include:

- Patient visits to healthcare professionals including GPs, diabetes nurses and consultant diabetologists for:
  - Monitoring
  - Transfer in treatment
- Diabetic nurse time outside of patient visits (eg, telephone calls, especially likely when transferring treatment)
- Home blood glucose monitoring strips
- Inpatient stays
Development of an economic evaluation of diagnostic strategies

- Accident and emergency visits (eg, for major hypoglycaemic events)
- Long-term care (eg, retinopathy screening)

For some of the strategies, there will be a one-off cost associated with implementation of the strategy itself, as well as likely ongoing costs for maintenance or training.

Treatment costs will include the cost of drug acquisition, taken from the most recent BNF (currently BNF6449), as well as any drug administration costs. There will also be a one-off cost for dietary advice for patients transferring off all treatment. In addition to the treatment costs, the model will include treatment transfer costs, for example, the costs for diabetes nurse time for monitoring of patients during transfer of treatment as estimated from the UNITED study.

A major cost component will be the costs of diabetes-related complications experienced during a patient’s lifetime. These cost estimates will be based on the most recent NHS Reference costs (currently50) and data from the literature.

Outcomes
The primary outcome will be the cost per QALY gained associated with each test–treatment strategy in comparison with the other strategies. An incremental analysis will be undertaken as all strategies to be modelled are realistic alternatives to each other. Secondary outcomes will include the cost per life-year gained, the cost per case identified and the cost per successful treatment transfer.

Base case perspective, discounting and time horizon
As preferred by NICE, the perspective of the model will be that of the NHS and Personal Social Services (PSS), with all costs and outcomes after the first year discounted at an annual rate of 3.5%.48 A lifetime horizon is modelled.

Internal validation
The decision model will undergo thorough testing and debugging by the model developer, and will be checked by a second experienced decision modeller. Internal validation of the decision model will be undertaken using data from the UNITED study.

DISCUSSION
In this paper, we have described the design and development of a new model for evaluating the long-term clinical effectiveness and cost-effectiveness of test–treatment strategies for patients with monogenic diabetes. Using critical appraisal methods and explicit expert input, the test–treatment strategies and model structure have been defined. Defining a model structure for any economic evaluation requires decisions to be made. However, the results of decision models are highly dependent on the range of comparators used, the decisions and assumptions regarding model structure as well as the evidence to inform parameters.15 Thus, explicit definition of the model with expert input and critical appraisal of existing models provides a justifiable model structure, lending credibility to the decision model and the subsequent cost-effectiveness results.

Although much of the model structure has been informed either by literature or experts, arbitrary choices have still been made. For instance, the time horizon of the short-term decision model is 16 months, based on the UNITED pathway: 4 months from initial test to treatment change plus 12-month treatment change follow-up. This is based on the length of the UNITED study, with the 12-month follow-up data used to predict long-term events in the IMS CDM. It is not clear whether outcomes at 12-month follow-up are the best data to predict long-term events in the IMS CDM. However, decision modelling allows investigation of the impact of such choices through sensitivity analysis.

More important is the validity of the model—that is, its ability to accurately predict the outcome or other relevant data on which the model was not originally based. As there are less data on monogenic diabetes, all available data on the test–treatment strategies and care pathways have or will be used to inform and/or parameterise the short-term model. Thus, there are no data available to allow external validation of the short-term model. Similarly, although the IMS CDM has undergone internal and external validation for type 1 and type 2 cohorts of patients, there has been no validation of this model, or any diabetes model, for monogenic diabetes. This further highlights the importance of face validity of the model, including the strategies to be evaluated and the model structure.

The next steps in developing the decision model are:
(1) to validate the short-term decision tree model when relevant data from the UNITED study are available and
(2) to identify relevant and most up-to-date data to populate the decision model.

CONCLUSIONS
Economic evaluation of test–treatment strategies in monogenic diabetes is difficult because of the possible number of realistic test–treatment strategies and associated care pathways. However, it is important to define realistic alternative strategies and to have an informed and defensible model structure as this is likely to impact on the cost-effectiveness. This paper demonstrated the feasibility of the explicit use of critical appraisal methods and expert consultation approaches for defining the strategies and model structure, and similar methods can be used by modellers in other conditions for developing decision models.

Acknowledgements We would like to thank the following members of the UNITED study team for their advice, input and discussion on the development of the decision model: Professor Andrew Hattersley, Dr Maggie Shepherd, Dr Beverley Shields, Michelle Hudson, Dr Tim McDonald, Dr Rachel Besser (University of Exeter Medical School), Professor Sian Ellard, Kevin Colclough (Royal Devon and Exeter NHS Foundation Trust, Exeter). We also thank all members of the UNITED Steering Group for their advice and discussion of the
model structure. We are grateful to Professor Katherine Payne for her time and effort in reviewing a previous version of this manuscript and Professor Norman Waugh for comments. We would also like to thank IMS Health for the use of the IMS CDM, in particular thanks to Dr David Grant. This work presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-041), a parallel funding partnership between the Wellcome Trust and the Department of Health. The views expressed in this publication are those of the authors and not necessarily those of the Wellcome Trust or the Department of Health.

Contributors
JP led the development of the economic evaluation, consulted with experts, carried out the systematic assessment of published diabetes models and drafted the manuscript. RA and CH contributed to the development of the economic model, discussion with experts and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding
Health Innovation Challenge Fund. (grant number HICF-1009-041), a parallel funding partnership between the Wellcome Trust and the Department of Health.

Competing interests
None.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
Data used in the development of the model-based economic evaluation are available in the manuscript text and the web appendix.

REFERENCES
1. Pearson ER, Starkey B, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275–81.
2. Pearson E, Liddell W, Shepherd M, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1 gene mutations: evidence for pharmacogenetics in diabetes. Diabetic Med 2000;17:543–5.
3. Hattersley AT. Molecular genetics goes to the diabetes clinic. Clin Med 2005;5:476–81.
4. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200–13.
5. Shepherd M, Shields B, Ellard S, et al. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabetic Med 2009;26:437–41.
6. Hattersley A, Bruining J, Shield J, et al. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl 12):33–42.
7. Moller AM, Dalgaard LT, Pociot F, et al. Mutations in the hepatocyte nuclear factor-1a gene in Caucasian families originally classified as having type I diabetes. Diabetologia 1998;41:1528–31.
8. UK Genetic Testing Network. http://www.ukgttn.nhs.uk/ghtn/Home (accessed 10 May 2013).
9. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504–8.
10. Shepherd M, Hattersley A, Ellard S. Integration of the MODY link nurse project: 20-month evaluation. J Diabetes Nura 2005;9:47–52.
11. Shields BM, McDonald TJ, Ellard S, et al. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012;55:1265–72.
12. Besser REJ, Shepherd MH, McDonald TJ, et al. Urinary c-peptide-to-creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1c/hepatocyte nuclear factor 4α-maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34:1–6.
13. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabetic Med 2011;28:1028–33.
14. National Institute for Health and Clinical Excellence—Centre for Health Technology Evaluation. Diagnostics assessment programme—interim methods statement (pilot), Version 8, 2010.
15. Weinstein MC, O’Brien BJ, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices—modeling studies. Value Health 2003;6:9–17.
16. Kallenthaler E, Tappenden P, Paisley S, et al. NISE DSU Technical Support Document 13: Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models. 2011.
17. Robinson S. Conceptual modelling for simulation part I: definition and requirements. J Oper Res Soc 2008;59:278–90.
18. Price MJ, Welton NJ, Briggs AH, et al. Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. Value Health 2011;14:205–18.
19. Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force 1. Med Decis Making 2012;32:667–77.
20. Roberts M, Russell LB, Paltiel DA, et al. Conceptualizing a model: a report of the ISPOR-SMDM modeling good practices task force 2. Med Decis Making 2012;32:678–89.
21. Yi Y, Phillips Z, Bergman G, et al. Economic models in type 2 diabetes. Curr Med Res Opin 2010;26:2105–18.
22. Taride JE, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 2010;28:255–77.
23. American Diabetes Association Consensus Panel. Guidelines for computer modelling of diabetes and its complications. Diabetes Care 2004;27:2262–5.
24. Hattersley A, Bruining J, Shield J, et al. ISPAD Clinical Practice Consensus Guidelines 2006–2007—the diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006;7:352–60.
25. Besser REJ, Ludvigsson J, Jones AG, et al. Urine c-peptide creatinine ratio is a non-invasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011;34:1–3.
26. Abdul-Rasoul M, Habib H, Al-Khouyry M. ‘The honeymoon phase’ in children with type I diabetes mellitus: frequency, duration and influential factors. Pediatr Diabetes 2006;7:101–7.
27. Bellanne-Chantelot C, Levy DJ, Carette C, et al. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to common genetic anomalies of the HNF1A gene. J Clin Endocrinol Metab 2011;96:E1346–51.
28. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:SS–26.
29. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetic Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747–59.
30. Eddy DM, Schliessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093–101.
31. Mueller E, Maxion-Bergmann S, Gultyaev D, et al. Development and validation of the ARCHIMEDES model: a tool to assess the efficacy and cost-effectiveness of antihypertensive and long-term effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219–36.
32. DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. J Am Med Assoc 1996;276:1408–15.
33. Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the diabetes mellitus Model inpatients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007;45:203–20.
34. Eastman RC, Javitt JC, Herman WC, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725–34.
35. Eastman RC, Javitt JC, Herman WC, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–44.
36. Brown JB, Russell A, Chan W, et al. The global diabetes model: user-friendly version 3.0. Diabetes Res Clin Pract 2000;50(Suppl 3):S15–46.
37. Chen J, Alicea E, Yin D, et al. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes. Obes Metab 2008;10(Suppl 1):33–47.
38. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001;44:2140–55.
39. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and
serum cholesterol level reduction for type 2 diabetes. J Am Med Assoc 2002;287:2542–51.

40. Palmer AJ, Roze S, Valentine WJ, et al. Computer modeling of diabetes and its complications—A report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638–46.

41. Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:11.

42. Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004;22:321–41.

43. Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22–33.

44. Fajans SS, Bell GI, Bowden DW, et al. Maturity-onset diabetes of the young. Life Sci 1994;55:413–22.

45. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43:339–57.

46. Steele AM, Shields BM, Shepherd M, et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabetic Med 2010;27:157–61.

47. Isomaa B, Henriksson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998;41:467–73.

48. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008.

49. British National Formulary 64:2012.

50. Department of Health. NHS reference costs 2010–2011. 2012.